EFFECT OF IVIG DOSE ON ANTI-AMYLOID BETA ANTIBODY AND AMYLOID BETA PEPTIDE BLOOD

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究探讨静脉注射免疫球蛋白(IVIg)被动免疫对轻、中度阿尔茨海默病(AD)患者的药代动力学、安全性和治疗效果。这项第一阶段研究的假设是，给轻到中度阿尔茨海默病(AD)患者使用静脉免疫球蛋白(百特生产的S/D伽玛卡)将增加他们血液中抗淀粉样贝塔多肽抗体和淀粉样贝塔多肽的水平。其具体目的是研究静脉注射免疫球蛋白在8名受试者中不同剂量和间隔的药代动力学反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The present study examines the pharmacokinetics, safety and therapeutic effects of passive immunization with intravenous immunoglobulin (IVIg) in patients with mild to moderate Alzheimer's (AD). The hypothesis of this Phase I study is that the administration of IVIg (Gammagard S/D, manufactured by Baxter) to patients with mild to moderate Alzheimer's Disease (AD) will increase the level of anti-amyloid beta peptide antibodies and amyloid beta peptide in their blood. The specific aim is to investigate the pharmacokinetic response to IVIg administration performed at varied doses and intervals in 8 subjects.